ARO Lung2
Alternative Names: ARO-Lung2Latest Information Update: 28 Jun 2024
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA (Inhalation)
- 08 May 2020 Preclinical trials in Chronic obstructive pulmonary disease in USA (Inhalation)
- 07 May 2020 Arrowhead Pharmaceuticals plans to file a clinical trial application for ARO Lung2 for chronic obstructive pulmonary diseases in first half of 2021